UBS keeps EUR 260.00 target for Sartorius Stedim stock

Published on 10/16/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 22, 2026. Sartorius Stedim stock costs EUR 215.70 on October 16, 2026, down 1.69 percent versus the Xetra close.

Analyst view and reporting date

UBS kept its EUR 260.00 target on October 15, 2026.
Sartorius Stedim will publish nine-month results on October 22, 2026.
Sartorius Stedim stock costs EUR 215.70 at 4:08 p.m. CEST on October 16, 2026, 1.69 percent below the Xetra close of October 15, 2026.
The company has a market capitalization of EUR 21.0 billion and a P/E ratio of 71.79.

Extreme Nahaufnahme einer transparenten Filtermembran mit Flüssigkeitstropfen — Sartorius Stedim Biotech Makroaufnahme einer transparenten Filtermembran mit feinen Flüssigkeitstropfen, ISIN FR0013154002, Illustration mit AI erstellt.

UBS kept its Buy rating and EUR 260.00 price target for Sartorius Stedim on October 15, 2026, according to Boersen-Zeitung. The target stands 20.54 percent above the EUR 215.70 price at Lang & Schwarz. Sartorius Stedim was trading at EUR 215.70 at Lang & Schwarz on October 16, 2026 at 4:08 p.m. CEST, down 1.69 percent versus the Xetra close of October 15, 2026 at EUR 219.40.

October 22 results set the next test

Sartorius Stedim has scheduled its nine-month 2026 results for October 22, 2026, according to the company's investor-relations page. The date gives the market a near-term test for the growth path highlighted by UBS. The company also lists fiscal year 2026 sales growth guidance of 6 to 10 percent in constant currencies and an underlying EBITDA margin above 31 percent.

Price remains below the yearly high

The Lang & Schwarz quote was EUR 9.30 below the 52-week high of EUR 225.00 and EUR 65.70 above the 52-week low of EUR 150.00 on October 16, 2026. The quote's bid was EUR 215.60 and its ask was EUR 215.80 at 4:08 p.m. CEST. The spread was EUR 0.20.

Valuation and upcoming figures

Sartorius Stedim had a market capitalization of EUR 21.0 billion, a P/E ratio of 71.79 and a dividend yield of 0.00 percent as of October 16, 2026. The valuation leaves the October 22 reporting date as the next concrete point for investors assessing whether the business can move toward its 2026 outlook. In fiscal year 2025, sales revenue was EUR 3.0 billion and rose 9.60 percent from the prior year, according to the company's investor-relations page.

Comparison with peers

Figures dated October 16, 2026.
Sartorius Stedim: minus 1.69 percent, P/E 71.79, market capitalization EUR 21.0 billion.
Danaher (NYSE, USD): minus 0.94 percent, P/E 40.73, market capitalization USD 161.2 billion.
Thermo Fisher Scientific (NYSE, USD): minus 0.64 percent, P/E 37.18, market capitalization USD 255.9 billion.

Price and target in perspective

UBS's EUR 260.00 target is 20.54 percent above the Lang & Schwarz price, while the stock remains 4.13 percent below its 52-week high. The October 22 results will provide the next scheduled company update. Sartorius Stedim was trading at EUR 215.70 at Lang & Schwarz on October 16, 2026 at 4:08 p.m. CEST, 1.69 percent below the Xetra close of October 15, 2026 at EUR 219.40. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.